Nephrotic syndrome with other morphologic changes
Methodology & AI Transparency ⓘ
Nephrotic syndrome with other morphologic changes Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Nephrotic syndrome with other morphologic changes is an ICD-10-CM indexed diagnosis (N04.8) within Chronic Kidney Disease & Electrolytes.
- 2 Real-world patient consensus: Federal ICD-10-CM code N04.8 categorizes Nephrotic syndrome with other morphologic changes under Chronic Kidney Disease & Electrolytes.
- 3 Typical cash cost range: Differential triage of Nephrotic syndrome with other morphologic changes (N04.8) utilizes NSAID/nephrotoxin avoidance [Nephrotic syndrome with other morphologic changes N04.8].
- 4 Top reported side effects / signs: Follow-up benchmark in Nephrotic syndrome with other morphologic changes: maintaining Serum Potassium, Bicarbonate in Nephrotic syndrome with other morphologic changes (N04.8: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.8).
Ask our AI Specialists anything about Nephrotic syndrome with other morphologic changes
What Is Nephrotic syndrome with other morphologic changes?
Nephrotic syndrome with other morphologic changes is an ICD-10-CM indexed diagnosis (N04.8) within Chronic Kidney Disease & Electrolytes. Clinical evaluation centers on NSAID/nephrotoxin avoidance [Nephrotic syndrome with other morphologic changes N04.8] alongside serial Serum Potassium, Bicarbonate in Nephrotic syndrome with other morphologic changes (N04.8: & Phosphorus) tracking (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.8)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Nephrotic syndrome with other morphologic changes (N04.8) features tubulointerstitial fibrosis [Nephrotic syndrome with other morphologic changes N04.8]. therapeutic stabilization in kidney & renal is verified against eGFR (Creatinine + in Nephrotic syndrome with other morphologic changes (N04.8: Cystatin C)).
Common Symptoms & Clinical Signs
- • Presentation of Nephrotic syndrome with other morphologic changes (N04.8): asymptomatic decline in in Nephrotic syndrome with other morphologic changes (N04.8: eGFR or persistent)
- • Secondary Nephrotic syndrome with other morphologic changes clinical sign: fluid retention in in Nephrotic syndrome with other morphologic changes (N04.8: ankles, hands, or)
- • Symptom flares in Nephrotic syndrome with other morphologic changes correlating with Serum Potassium, Bicarbonate in Nephrotic syndrome with other morphologic changes (N04.8: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.8)
- • Functional kidney & renal impact requiring NSAID/nephrotoxin avoidance [Nephrotic syndrome with other morphologic changes N04.8] evaluation (N04.8)
Nephrotic syndrome with other morphologic changes Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N04.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Nephrotic syndrome with other morphologic changes (N04.8: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N04.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Nephrotic syndrome with other morphologic changes (N04.8: Cystatin C)) | >= 90 mL/min/1.73m2 (N04.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Nephrotic syndrome with other morphologic changes (N04.8: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N04.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Nephrotic syndrome with other morphologic changes
Treatment selection for Nephrotic syndrome with other morphologic changes depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Nephrotic syndrome with other morphologic changes)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Circulating kidney injury molecule-1 (KIM-1) and association with outcome to These analyses suggest that elevated post-nephrectomy plasma KIM-1 level and kinetics are prognostic, supporting the hypothesis that KIM-1 is a biomarker for minimal residual disease in RCC. Annals of oncology : official journal of the European Society for Medical Oncology • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40885527 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Upacicalcet in Hemodialysis Patients with Secondary Upacicalcet, a novel injectable calcimimetic, is effective and safe for secondary hyperparathyroidism patients receiving HD. Clinical journal of the American Society of Nephrology : CJASN • 2023-10-01 • Phase III Randomized Trial | N = 103 | 88/100 | PMID 37696667 ↗ |
| New Insights on Benefits and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata: What a 312-Participant Study Found CKD-701 is a biosimilar to the reference ranibizumab in terms of efficacy, safety, and immunogenicity for the treatment of patients with nAMD. PloS one • 2022-01-15 • Phase III Randomized Trial | N = 312 | 87/100 | PMID 36374913 ↗ |
| Can This Approach Help? Inside the Latest Research on Antioxidant and anti-inflammatory activities of avasopasem manganese in Older mice and humans are more susceptible to cisplatin-induced kidney injury, and treatment with AVA mitigates age-associated damage. Redox biology • 2024-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38215546 ↗ |
| Can This Approach Help? Inside the Latest Research on Bevacizumab-induced high blood pressure and proteinuria: a genome-wide study of The results from the largest study of bevacizumab toxicity provide new markers of drug safety for further evaluations. British journal of cancer • 2022-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34616010 ↗ |
Nephrotic syndrome with other morphologic changes Patient Community & “People Like Me” Threads
Filter Nephrotic syndrome with other morphologic changes community threads and patient logs by age, biological sex, dosage, and treatment duration.